Hansa Biopharma AB (publ) (HNSBF) Discusses Out-Licensing Agreement With SERB for Idefirix Commercialization in Europe and MENA Transcript
Hansa Biopharma AB has announced an out-licensing agreement with SERB for the commercialization of Idefirix in Europe and the MENA region. This agreement aims to enhance the availability of Idefirix, a treatment for patients with certain kidney conditions. The collaboration is expected to leverage SERB's expertise in the pharmaceutical market to optimize the product's reach and impact.
- ▪Hansa Biopharma has entered into an out-licensing agreement with SERB.
- ▪The agreement focuses on the commercialization of Idefirix in Europe and MENA.
- ▪Idefirix is designed for patients with specific kidney conditions.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4906547-hansa-biopharma-ab-publ-hnsbf-discusses-out-licensing-agreement-with-serb-for-idefirix"},"author":{"@type":"Person","name":"SA Transcripts","url":"https://seekingalpha.com/author/sa-transcripts"},"publisher":{"@context":"http://schema.org","@type":"Organization","address":{"@type":"PostalAddress","streetAddress":"244 5th Ave","addressLocality":"New York","addressRegion":"NY","postalCode":"10001","addressCountry":"US"},"alternateName":["SeekingAlpha","SA"],"brand":[{"@type":"Brand","name":"Seeking Alpha Premium","url":"https://seekingalpha.com/subscriptions/premium"},{"@type":"Brand","name":"Seeking Alpha…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
